Empiric Antibiotic Therapy in Suspected Sepsis: Impact of Gentamicin-Based Regimens on Incident Renal Failure and Mortality
Abstract
Background: The efficacy and safety of administering a narrow-spectrum β-lactam and gentamicin as empirical therapy for community-acquired sepsis has been questioned. We compared the efficacy and safety of this combination with that of broad-spectrum β-lactams (cefotaxime, piperacillin-tazobactam, or meropenem) in patients with suspected sepsis.
Methods: In this retrospective study, we included patients initiated on narrow-spectrum β-lactam/gentamicin or broad-spectrum β-lactams for suspected sepsis between January 2017 and December 2022. Patients without baseline creatinine and at least 1 subsequent creatinine measurement were excluded. We compared the impact of antibiotic regimens using a 5-level ordinal outcome scale ranging from no acute kidney injury (AKI) to all-cause death during 30-day follow-up.
Results: Among 1917 patients, 33.1% received narrow-spectrum β-lactam/gentamicin, and 66.9% received broad-spectrum β-lactams. Patients initiated on broad-spectrum β-lactams had more comorbidities, had lower estimated glomerular filtration rate on admission, and more frequently required treatment with noradrenaline, respiratory support, and admission to the intensive care and medical intermediate care units. Therapy with broad-spectrum β-lactams was associated with a higher posttreatment stage of AKI or death (adjusted odds ratio, 1.61 [95% confidence interval, 1.27-2.04]). We found no significant association between cumulative dose of gentamicin and peak creatinine value.…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 1,917 participants or records.
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.